GEN News Highlights

Alzheimer's Disease Research Gets More Funds

(Page
1
of
1)

The NIH, through the Office of the Director and the National Center for Advancing Translational Sciences, awarded Factor Bioscience two Small Business Innovation Research (SBIR) grants to accelerate the development of new treatments for Alzheimer's Disease.

The first project will use Factor's RiboSlice™ gene-editing technology to generate rodent models of Alzheimer's. The second project will combine RiboSlice technology with Factor's integration-free reprogramming and directed-differentiation technologies to generate a library of human neural cells containing defined mutations in Alzheimer's-associated genes. "We believe that this library has the potential to dramatically accelerate the identification of new Alzheimer's drug candidates by shifting high-content efficacy testing to an earlier stage of the drug-development process," explains project leader Christopher Rohde, Ph.D., COO and director of high-throughput technologies.

"Alzheimer's research has been held back by a lack of good models. These models are the critical missing links needed to understand the fundamental biology of Alzheimer's and to develop effective treatments," says Matt Angel, Ph.D., Factor's CEO. "With the support of the National Alzheimer's Plan, we will focus these powerful new methods on Alzheimer's Disease to elucidate and advance new, more effective treatments."

Earlier this year the National Institute on Aging (NIA), part of the NIH, developed the International Alzheimer’s Disease Research Portfolio (IADRP), a database designed to enable public and private funders of Alzheimer’s research to coordinate research planning, leverage resources, avoid duplication of funding efforts, and identify new opportunities in promising areas of growth. This resource was developed in collaboration with the Alzheimer’s Association and is currently hosted and maintained by NIA.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.